Drugs / AFNT-211
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06105021 | Mar 2024 → Dec 2025 overdue | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Affini-T Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFNT-211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06105021 ↗ |
| Modality | Cell therapy | “AFNT-211 is a cellular therapy consisting of autologous CD4+ and CD8+ T cells engineered to express a human leukocyte antigen-A (HLA-A)\*11:01-restricted Kirsten rat sarcoma...” NCT06105021 ↗ |
| Target | KRAS | “AFNT-211 is a cellular therapy consisting of autologous CD4+ and CD8+ T cells engineered to express a human leukocyte antigen-A (HLA-A)\*11:01-restricted Kirsten rat sarcoma...” NCT06105021 ↗ |